K. Atchison

发表

Age-dependent disruption in hippocampal theta oscillation in amyloid-β overproducing transgenic mice

Liam Scott, T. Kiss, M. Hajós, 2012, Neurobiology of Aging.

Discovery of a novel series of Notch-sparing gamma-secretase inhibitors.

B. Harrison, D. Huryn, J. Ellingboe, 2008, Bioorganic & medicinal chemistry letters.

Bisindolylmaleimides linked to DNA minor groove binding lexitropsins: synthesis, inhibitory activity against topoisomerase I, and biological evaluation.

J. Lown,, K. Atchison, R. Gupta, 1996, Journal of medicinal chemistry.

In Vitro and In Vivo Activities of Syn2190, a Novel β-Lactamase Inhibitor

R. Micetich, K. Atchison, H. Atwal, 1999, Antimicrobial Agents and Chemotherapy.

JPET #152975 1 TITLE: GSI-953 (begacestat): A novel, selective thiophene sulfonamide inhibitor of APP γ-secretase for the treatment of Alzheimer’s disease

T. Comery, B. Harrison, M. Pangalos, 2009 .

Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease

Derek H. Oakley, B. Hyman, J. Steen, 2020, Nature Medicine.

Synthesis and beta-lactamase inhibitory activity of 6-[(1-heteroarylthioethyl-1,2,3-triazol-4-yl)-methylene]penam sulfones.

R. Micetich, K. Atchison, O. Phillips, 1994, Journal of antibiotics (Tokyo. 1968).

Synthesis and β-Lactamase Inhibitory Activity of 6-((1- Heteroarylthioethyl-1,2,3-triazol-4-yl)methylene)penam Sulfones.

R. Micetich, K. Atchison, O. Phillips, 1995 .

Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.

Gregory W. Kauffman, Chakrapani Subramanyam, L. Pustilnik, 2012, Journal of medicinal chemistry.

Begacestat (GSI-953): A Novel, Selective Thiophene Sulfonamide Inhibitor of Amyloid Precursor Protein γ-Secretase for the Treatment of Alzheimer's Disease

T. Comery, B. Harrison, M. Pangalos, 2009, Journal of Pharmacology and Experimental Therapeutics.

Alternative method of oral administration by peanut butter pellet formulation results in target engagement of BACE1 and attenuation of gavage-induced stress responses in mice

K. Atchison, D. Riddell, C. Gonzales, 2014, Pharmacology Biochemistry and Behavior.

Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors

Graham M. West, Sherry L. Niessen, Claude Ambroise, 2016, Nature Communications.

Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels

M. Pangalos, K. Atchison, D. Riddell, 2008, The Journal of Neuroscience.

Enhanced clearance of Aβ in brain by sustaining the plasmin proteolysis cascade

T. Comery, A. Robichaud, M. Pangalos, 2008, Proceedings of the National Academy of Sciences.

Synthesis of podophyllotoxin congeners as potential DNA topoisomerase II inhibitors.

R. Micetich, K. Atchison, A. Kamal, 1995, Anti-cancer drug design.

Discovery of a series of efficient, centrally efficacious BACE1 inhibitors through structure-based drug design.

K. Parris, K. Atchison, D. Riddell, 2015, Journal of medicinal chemistry.

Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease.

T. Comery, K. Fan, B. Harrison, 2008, Journal of medicinal chemistry.

Acute γ-Secretase Inhibition Improves Contextual Fear Conditioning in the Tg2576 Mouse Model of Alzheimer's Disease

T. Comery, K. Marquis, M. Pangalos, 2005, The Journal of Neuroscience.

Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease.

T. Comery, K. Marquis, M. Pangalos, 2005, The Journal of neuroscience : the official journal of the Society for Neuroscience.

Effects of the γ-secretase inhibitor semagacestat on hippocampal neuronal network oscillation

T. Kiss, M. Hajós, É. Hajós‐Korcsok, 2013, Front. Pharmacol..

Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug–Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors

J. Pandit, K. Parris, Eric F. Johnson, 2015, Journal of medicinal chemistry.

Quantitative Pharmacokinetic/Pharmacodynamic Analyses Suggest That the 129/SVE Mouse Is a Suitable Preclinical Pharmacology Model for Identifying Small-Molecule γ-Secretase Inhibitors

L. Pustilnik, A. Stepan, K. Atchison, 2011, Journal of Pharmacology and Experimental Therapeutics.

Studies on monobactams I. Synthesis and β-lactamase inhibitory activity of 4-substituted 3-[(N-methyl-1,2,3-triazol-4-yl)-methylene]-2-azetidinone-1-sulfonates

R. Micetich, K. Atchison, O. Phillips, 1998 .

Chemical modification of tazobactam. Synthesis of 2 beta-[(4-substituted)-1,2,3-triazol-1-yl]methyl penicillanic acid sulfone derivatives.

E. Setti, R. Micetich, K. Atchison, 1995, Journal of antibiotics (Tokyo. 1968).

Studies on Monobactams. Part 1. Synthesis and β‐Lactamase Inhibitory Activity of 4‐Substituted 3‐[(N‐Methyl‐1,2,3‐triazol‐4‐yl)methylene]‐2‐azetidinone‐1‐sulfonates.

R. Micetich, K. Atchison, O. Phillips, 1999 .

Chemical Modification of Tazobactam ‐ Synthesis of 2β‐((4‐ Substituted)‐1,2,3‐triazol‐1‐yl)methyl Penicillanic Acid Sulfone Derivatives.

E. Setti, R. Micetich, K. Atchison, 1996 .

Studies on penam sulfones. I. Synthesis and beta-lactamase inhibitory activity of 2 beta-alkoxycarbonyl penicillanic acid sulfones.

E. Setti, R. Micetich, K. Atchison, 1996, Journal of antibiotics (Tokyo. 1968).

Studies on Penam Sulfones Inhibitory Activity of 2/f-Carboxamide Penicillanic Acid Sulfones

Narender, L. Setti, R. Micetich, 2006 .

Aminomethyl-Derived Beta Secretase (BACE1) Inhibitors: Engaging Gly230 without an Anilide Functionality

K. Parris, Eric F. Johnson, K. Atchison, 2016, Journal of medicinal chemistry.

Pharmacological Assessment of γ-Secretase Activity from Rodent and Human Brain

K. Bales, K. Atchison, Martin Pettersson, 2012 .

Synthesis and structure-activity relationship of a novel series of heterocyclic sulfonamide gamma-secretase inhibitors.

B. Harrison, D. Huryn, K. Atchison, 2009, Bioorganic & medicinal chemistry.

(S)-N-(5-Chlorothiophene-2-sulfonyl)-beta,beta-diethylalaninol a Notch-1-sparing gamma-secretase inhibitor.

T. Comery, B. Harrison, Z. Wang, 2009, Bioorganic & medicinal chemistry letters.

Metabolism-directed design of oxetane-containing arylsulfonamide derivatives as γ-secretase inhibitors.

L. Pustilnik, A. Stepan, R. Obach, 2011, Journal of medicinal chemistry.

Utilizing CYP2D6 and BACE1 Structure Complexes to Reduce Risk of Drug-Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors

K. Parris, Eric F. Johnson, S. Sakya, 2015 .

GSI-953 is a potent APP-selective gamma-secretase inhibitor for the treatment of Alzheimer's disease

T. Comery, B. Harrison, M. Pangalos, 2008, Alzheimer's & Dementia.